705 related articles for article (PubMed ID: 23942868)
1. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
3. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
[TBL] [Abstract][Full Text] [Related]
4. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
Furst DE; Shaikh SA; Greenwald M; Bennett B; Davies O; Luijtens K; Staelens F; Koetse W; Bertin P
Arthritis Care Res (Hoboken); 2015 Feb; 67(2):151-60. PubMed ID: 25302624
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
6. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Kavanaugh A; Gladman D; van der Heijde D; Purcaru O; Mease P
Ann Rheum Dis; 2015 Jan; 74(1):44-51. PubMed ID: 24942382
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
8. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study.
Gladman D; Fleischmann R; Coteur G; Woltering F; Mease PJ
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1085-92. PubMed ID: 24339179
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
[TBL] [Abstract][Full Text] [Related]
11. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.
van der Heijde D; Deodhar A; FitzGerald O; Fleischmann R; Gladman D; Gottlieb AB; Hoepken B; Bauer L; Irvin-Sellers O; Khraishi M; Peterson L; Turkiewicz A; Wollenhaupt J; Mease PJ
RMD Open; 2018; 4(1):e000582. PubMed ID: 29556416
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
[TBL] [Abstract][Full Text] [Related]
18. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
Mease P; Deodhar A; Fleischmann R; Wollenhaupt J; Gladman D; Leszczyński P; Vitek P; Turkiewicz A; Khraishi M; FitzGerald O; Landewé R; de Longueville M; Hoepken B; Peterson L; van der Heijde D
RMD Open; 2015; 1(1):e000119. PubMed ID: 26509074
[TBL] [Abstract][Full Text] [Related]
19. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
